Cell Genesys expands enrollment of phase 1 trial of CG0070 for treatment of bladder cancer

By Lisa Kerner

Charlotte, N.C., July 18 - Cell Genesys, Inc. opened enrollment for an expanded multi-center phase 1 clinical trial of CG0070 to evaluate escalating multiple-dose regimens of CG0070 in patients with recurrent bladder cancer.

Up to 45 additional patients who have failed previous therapy with Bacillus Calmette-Guerin (BCG), the current standard therapy for recurrent bladder cancer, will be included in the open-label, dose-escalating study, according to a company news release.

Recently reported interim safety and efficacy data for single-dose administration of CG0070 prompted the trial expansion, according to Cell Genesys.

CG0070 is an oncolytic virus therapy being developed with Novartis AG that has two mechanisms of action to destroy cancer cells.

"We are optimistic that the dual mechanism of action of CG0070 might result in enhanced local antitumor activity as well as potential systemic antitumor immunity following local administration," president and chief operating officer Joseph J. Vallner said in the release.

About 61,500 new cases of bladder cancer will be diagnosed in 2006, with the majority being superficial bladder cancer, according to American Cancer Society estimates.

Cell Genesys, located in South San Francisco, Calif., develops and commercializes novel biological therapies for the treatment of cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.